MedPath

Biological characteristics of sensitization in patients with MIRI

Phase 1
Conditions
Myocardial ischemia reperfusion injury
Registration Number
ChiCTR2400088845
Lead Sponsor
Shaanxi University of Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

MIRI patients:<br>(1) meeting the diagnostic criteria of non-ST elevation acute coronary syndrome in 2023 ESC Guidelines for the management of acute coronary syndromes.<br>(2) received percutaneous coronary intervention within a week.<br>(3) aged 18 to 85 years.<br>(4) willing to participate in this study, and sign on informed consent.<br>Healthy subjects:<br>(1) received a health examination within a week, and confirmed to be in good health.<br>(2) aged 18 to 85 years.<br>(3) willing to participate in this study, and sign on informed consent.

Exclusion Criteria

(1) diagnosed as ST-elevation myocardial infarction, with persistent ST-segment elevation or ST-segment elevation equivalents on electrocardiogram.<br>(2) combined with disorders of rhythm, disorders of the heart, muscles, valves, and pericardium, and peripheral vascular disease.<br>(3) suffering from neoplastic disorders, hematopoietic disorders, disorders of hemostasis, infectious diseases, immune-mediated, inflammatory, and rheumatologic disorders.<br>(4) combined with fever.<br>(5) suffering from psychiatric disorders, and unable to cooperate.<br>(6) participating in any other study within 3 months.

Study & Design

Study Type
Observational study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
mRNA;
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath